Media
Press Releases
HDT Bio Partners with Brazil’s SENAI CIMATEC to Advance RNA COVID-19 Vaccine to Fight Pandemic
Agreement extends HDT Bio’s international COVID 19 vaccine partnerships as part of its long-term goal of changing the global-health paradigm to address global-health inequity The company’s RNA-based vaccine offers simpler manufacturing, easier deployment without the...
In the News
Bioprocess Online: Personalized Or Off The Shelf? Differentiated Approaches To Cancer Vaccines
Click here to view article
Bioprocess Online Live: What Makes A Good Therapeutic Cancer Vaccine Antigen?
Click here to view article
Bioprocess Online: What Makes A Good Therapeutic Cancer Vaccine Antigen?
Click here to view article
Conversations Life Science Leaders Aren’t Having: Global Impact and Innovation – with Steve Reed
Click here to view article
Slice of Healthcare: #32 – Steve Reed, Co-Founder & Chief Executive Officer Of HDT Bio
Click here to view article
Scrip Citeline: Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology
Click here to view article
BioSpace: Pricing, Politics and AI To Take Center Stage in 2024
Click here to view article
Vial: First in Human Episode #50 featuring Steven Reed
Click here to view article
Precision Vaccinations: $749,000 Contract Awarded for Next Generation RNA Vaccine Production
Click here to view article
Advancing RNA: RNA Vaccines: Just Scratching The Surface
Click here to view article